Processing

Please wait...

Settings

Settings

Goto Application

1. EP3892268 - USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS

Office
European Patent Office
Application Number 20315150
Application Date 10.04.2020
Publication Number 3892268
Publication Date 13.10.2021
Publication Kind A1
IPC
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 31/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
20for DNA viruses
CPC
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61P 31/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
20for DNA viruses
Applicants INST NAT SANTE RECH MED
UNIV CLAUDE BERNARD LYON
CENTRE NAT RECH SCIENT
ECOLE NORMALE SUPERIEURE LYON
UNIV AIX MARSEILLE
INSTITUT DE RECH POUR LE DEVELOPPEMENT IRD
Designated States
Priority Data 20315150 10.04.2020 EP
Title
(DE) VERWENDUNG VON VIDOFLUDIMUS ZUR BEHANDLUNG VON CORONAVIRUSINFEKTIONEN
(EN) USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
(FR) UTILISATION DE VIDOFLUDIMUS POUR LE TRAITEMENT DES INFECTIONS À CORONAVIRUS
Abstract
(EN) Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new betacoronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that Vidofludimus is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.
Related patent documents